BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals. As ...

The U.S. has shifted to a campaign of economic warfare, after a dozen waves of airstrikes in July failed to force Tehran to ...

Salesforce's stock had its second-best day on record following earnings, as Wall Street shows renewed confidence in CEO Marc ...

Marvell Technology shares fell 8% in premarket trading despite a second-quarter revenue beat, as its fiscal 2028 outlook ...

A federal judge on Thursday halted — at least for now — attempts to implement President Donald Trump's executive order ...

Gamers got their first look at gameplay of the latest Grand Theft Auto title in a release on Netflix, with Christopher Dring, ...

Maxime Darmet, Senior Economist at Allianz Trade, discusses his outlook for the French presidential elections, and explains ...

CNBC's Kai Nicol-Schwarz discusses how Nvidia is bolstering support for Chinese open AI models, even as it warns of potential ...

The Zephirin Group analyst Lenny Zephirin discusses Manycore’s first-half results, including slowing domestic growth, ...

Kamran Bokhari, Strategic Forecaster and Senior Resident Fellow at the Middle East Policy Council, says a possible strategic ...

Chez Anbu, Head of Wealth Advisory at OCBC, talks expectations ahead of Fed Chairman Kevin Warsh's Jackson Hole speech - ...

Sonal Varma, Chief Economist, India & Asia (excl. Japan) at Nomura explains India's recent consumption recovery and how it ...